Second, the system was initially built to target CP-CRE and although additional high-impact organisms have been added, some users may not be sufficiently concerned about CP-CRE given the relative infrequency of CP-CRE in the VA system (eg, 2 CP-CRE healthcare-associated infections [HAIs] reported monthly in 2023) such that VABA adoption may be perceived as lower priority. This evidence concerns the gene CP and nosocomial infection.